NCT07535372: NAUTILUS

ASO Treatment for Syndromic Craniosynostoses

Not yet recruiting Last updated 17 April 2026

What this trial tests

trial testing Design of patient specific ASO in Craniosynostoses in 12 participants. Not yet recruiting.

Timeline

20 April 2026

Primary endpoint
20 April 2027

20 April 2028

Quick facts

Lead sponsor	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	12
Start date	20 April 2026
Primary completion	20 April 2027
Estimated completion	20 April 2028
Sites	1 location across France

Drugs / interventions tested

• Design of patient specific ASO

Conditions studied

• Craniosynostoses — all drugs for Craniosynostoses →
• Crouzon Syndrome — all drugs for Crouzon Syndrome →
• Saethre Chotzen Syndrome — all drugs for Saethre Chotzen Syndrome →
• Muenke Syndrome — all drugs for Muenke Syndrome →

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Who can join

Under 5, any sex, with Craniosynostoses or Crouzon Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Syndromic craniosynostoses (SCS) are rare genetic disorders defined by premature cranial suture fusion, resulting in abnormal craniofacial development and constrained brain growth. These conditions, including Muenke, Saethre-Chotzen, Crouzon, Apert, Pfeiffer and craniofrontonasal syndromes, are typically caused by gain- or loss-of-function variants in key regulators of suture biology such as FGFR1/2/3, TWIST1 and TCF12. Current management is exclusively surgical, relying on early cranial vault remodelling and subsequent reconstructive procedures, which carry substantial risks (e.g. blood loss, infection, re-synostosis) and do not address the underlying molecular etiology.

Recent advances in RNA-based therapeutics have demonstrated the potential of mutation-specific approaches to normalize aberrant osteogenic differentiation in patient-derived cells. However, clinical translation remains limited by inefficient delivery and lack of sustained therapeutic activity. The NAUTILUS project aims to overcome these barriers by developing a non-invasive, ultra-personalized therapeutic platform based on mutation-specific antisense oligonucleotides (ASOs) delivered via a nano-engineered system.

The project will design and validate patient-tailored ASOs targeting the molecular drivers of SCS, with the goal of either silencing pathogenic gain-of-function alleles or restoring physiological expression in loss-of-function contexts. Functional efficacy will be assessed in patient-derived cellular models by evaluating transcript modulation and rescue of protein function. In parallel, NAUTILUS will optimize a nano-ink delivery platform combining PLGA-PEG-bis-sulfone nanoparticles with a GelMA-based hydrogel scaffold, enabling localized, controlled, and sustained ASO release within the cranial suture niche.

Preclinical validation in relevant mouse models will assess the capacity of this platform to delay or prevent pathological suture ossification, ultimately reducing the need for repeated surgical interventions. By directly targeting the genetic basis of disease, NAUTILUS proposes a transformative approach to SCS management. This strategy has the potential to decrease treatment invasiveness, improve clinical outcomes, and enhance quality of life, establishing a precision medicine paradigm for rare craniofacial disorders.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.